Skip to content

Author

Carlo Serra

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Evaluation metrics for synthetic medical imaging.

BACKGROUND Advances in generative artificial intelligence (AI) have accelerated the development and application of synthetic medical imaging. Despite this rapid progress, the evaluation of synthetic medical images remains heterogeneous, with numerous metrics proposed to assess fidelity, realism, diversity, and clinical validity. Currently, no standardized framework exists to guide the selection, interpretation, or comparison of these metrics, limiting reproducibility and cross-study comparability. This systematic review aims to comprehensively summarize and categorize existing metrics used to assess these complementary dimensions of synthetic medical images. METHODS A systematic review was conducted in accordance with PRISMA guidelines. PubMed/MEDLINE, EMBASE, Scopus, and arXiv were searched for studies published between 2015 and April 30, 2025, supplemented by citation screening of included studies. Eligible studies were full-text articles that applied or proposed metrics to evaluate the fidelity, realism, diversity, and/or clinical validity in synthetic medical images. RESULTS A total of 47 studies were included. Evaluation practices were highly heterogeneous. Expert evaluation (n = 25, 53%) and reference-based evaluations were most common (n = 25, 53%), followed by no-reference metrics (n = 24, 51%), and task-based evaluations (n = 24, 51%). The most commonly used individual metrics were peak signal-to-noise ratio (PSNR) (n = 16, 34%), structural similarity index (SSIM) (n = 15, 32%), mean absolute error (MAE) (n = 12, 26%), and Fréchet Inception Distance (FID) (n = 12, 26%). CONCLUSION Evaluation strategies for synthetic medical imaging showed substantial variability and no single metric captured fidelity, realism, diversity, and clinical validity simultaneously. Metric choice is often dictated by data availability rather than clinical purpose. A task-specific, layered evaluation framework could improve comparability and facilitate clinical adoption.

D. D. de Wilde, Benjamin Schärli, Kym Ackermann et al. · 0 citations
Open access Aug 2026

Automated deep learning-based segmentation and volumetric analysis of meningiomas.

INTRODUCTION Meningiomas are the most common primary intracranial tumors and are frequently monitored over extended periods. Volumetric assessment typically requires manual segmentation, which is time-consuming and associated with interrater variability. This study aimed to develop and validate a deep learning-based model for the automated segmentation of meningiomas and associated peritumoral edema on preoperative magnetic resonance imaging (MRI). METHODS We trained a standard nnU-Net deep learning model on contrast-enhanced T1-weighted and FLAIR MRI scans from 100 patients treated at the University Hospital of Zurich. The model was then externally validated on 88 cases from the meningioma SEG-Class dataset from the Cancer Imaging Archive. Segmentation performance was assessed using the Dice similarity coefficient, Jaccard index, and 95th percentile Hausdorff distance. RESULTS The model achieved mean Dice scores of 0.87 ± 0.23 for meningioma segmentation and 0.63 ± 0.38 for peritumoral edema in internal cross-validation. On the external validation set, the model achieved scores of 0.86 ± 0.17 for meningioma segmentation and 0.31 ± 0.35 for edema. CONCLUSION The deep learning model demonstrated high accuracy in segmenting meningiomas and modest performance for peritumoral edema. These results support the potential utility of automated segmentation tools in clinical workflows. Future work should focus on validating model performance across larger multi-center datasets.

D. de Wilde, Olivier Zanier, A. Alakmeh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.